These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Transplantation without maintenance corticosteroids in 1-haplotype and 2-haplotype HLA matched living-related renal transplant recipients treated with mycophenolate mofetil and cyclosporine. Kupin W; Venkat KK; Goggins M; Douzdjian V; Escobar F; Mozes M; Abouljoud M Transplant Proc; 1999; 31(1-2):744-5. PubMed ID: 10083317 [No Abstract] [Full Text] [Related]
3. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants. Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031 [No Abstract] [Full Text] [Related]
4. Comparison between mycophenolate mofetil and azathioprine based immunosuppression in pediatric renal transplantation from living related donors. Antoniadis A; Papachristou F; Gakis D; Takoudas D; Sotiriou I Transplant Proc; 1998 Dec; 30(8):4085-6. PubMed ID: 9865305 [No Abstract] [Full Text] [Related]
5. Improved primary transplant success rates using a triple regimen of cyclosporine microemulsion, mycophenolate mofetil and prednisone. Khauli RB; Medawar WA; Habbal AA; Birbari AE; Daouk MM; Abdelnoor AM; Uwaydah M; Rahman Bizri A; Sanjad S; Ayvazian PJ; Lovewell T; Stoff JS; Yang Fan P; Bigwood P; Harland R Transplant Proc; 2001 Aug; 33(5):2776-7. PubMed ID: 11498156 [No Abstract] [Full Text] [Related]
6. Triple therapy with mycophenolate mofetil versus azathioprine. Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512 [No Abstract] [Full Text] [Related]
14. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group. Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033 [No Abstract] [Full Text] [Related]
15. Tolerability of mycophenolate mofetil in organ transplant recipients. Schweizer RT; Meisterling LD Transplant Proc; 2001 May; 33(3):2309. PubMed ID: 11377540 [No Abstract] [Full Text] [Related]
16. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes. Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449 [No Abstract] [Full Text] [Related]
19. Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipients. Weber M; Ketchum RJ; Sellers M; Aradhye S; Deng S; Grossman R; Shaw L; Naji A; Barker C; Brayman KL Transplant Proc; 1997; 29(1-2):338-9. PubMed ID: 9123029 [No Abstract] [Full Text] [Related]
20. Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function. Liu B; Lin ZB; Ming CS; Zhang WJ; Chen ZS; Sha B; Zeng FJ; Chen S Transplant Proc; 2003 Feb; 35(1):87-8. PubMed ID: 12591319 [No Abstract] [Full Text] [Related] [Next] [New Search]